Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) FCF Margin (2016 - 2025)

Historic FCF Margin for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to 14.37%.

  • Tg Therapeutics' FCF Margin rose 2100.0% to 14.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 13.21%, marking a year-over-year decrease of 25900.0%. This contributed to the annual value of 12.33% for FY2024, which is 11200.0% up from last year.
  • As of Q3 2025, Tg Therapeutics' FCF Margin stood at 14.37%, which was up 2100.0% from 5.24% recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' FCF Margin peaked at 50.48% during Q3 2023, and registered a low of 36701.06% during Q3 2022.
  • Moreover, its 5-year median value for FCF Margin was 261.32% (2023), whereas its average is 5291.54%.
  • In the last 5 years, Tg Therapeutics' FCF Margin surged by 1533718800bps in 2021 and then crashed by -333867800bps in 2022.
  • Quarter analysis of 5 years shows Tg Therapeutics' FCF Margin stood at 3747.91% in 2021, then plummeted by -696bps to 29841.25% in 2022, then soared by 100bps to 30.04% in 2023, then increased by 21bps to 23.72% in 2024, then skyrocketed by 39bps to 14.37% in 2025.
  • Its FCF Margin stands at 14.37% for Q3 2025, versus 5.24% for Q2 2025 and 23.78% for Q1 2025.